Gilead Licenses Novel Immunotherapy From Jounce

 
• By Joseph Haas

Deal snapshot: Gilead’s latest significant cancer deal brings it a CCR8 binder, a novel preclinical immunotherapy, while Jounce finds a new deep-pocketed partner after the termination of its collaboration with Celgene.

Brainstorming Group of people Working Concept. Business team brainstorming. Marketing plan researching. Paperwork on the table, laptop and mobile phone.
With its deal with Jounce, Gilead continues to pick up new IO partners

More from Deals

More from Business